Eaton Vance Management Reata Pharmaceuticals Inc Call Options Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding RETA
# of Institutions
5Shares Held
62.7KCall Options Held
0Put Options Held
0About REATA PHARMACEUTICALS INC
- Ticker RETA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,583,200
- Description
- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...